A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.
Also called NCT06568471
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Registry
-
NCT06568471
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06568471. Randomized; triple masking; primary purpose treatment. Start 2024-11-16 (actual); primary completion 2026-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Condition
- Dyslipidemias
- Condition
- Primary Hypercholesterolemia
- Condition
- Heterozygous Familial Hypercholesterolemia
- Condition
- Hyperlipidemia; Mixed
- Condition
- Metabolic Disease
- Condition
- ASCVD
- Intervention (Drug)
- Lerodalcibep
- Intervention (Drug)
- matching placebo
- Lead sponsor
- Hasten Biopharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06568471- Content hash
add151570a74c68f93755845122c5c92cd69b0683bdf4d7b86bf5ddef390ae45